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Background: Next generation sequencing (NGS) is a state of the art technology for microRNA (miRNA) analysis.
The quantitative interpretation of the primary output of NGS i.e. the read counts for a miRNA sequence that can
vary by several orders of magnitude (1 to 107) remains incompletely understood.
Findings: NGS (SOLiD 3 technology) was performed on biopsies from 6 Barrett’s esophagus (BE) and 5 Gastroesophageal
Reflux Disease (GERD) patients. Read sequences were aligned to miRBase 18.0. Differential expression analysis was
adjusted for false discovery rate of 5%. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed for 36
miRNA in a validation cohort of 47 patients (27 BE and 20 GERD). Correlation coefficients, accuracy, precision and recall of
NGS compared to qRT-PCR were calculated. Increase in NGS reads was associated with progressively lower Cq values,
p < 0.05. Although absolute quantification between NGS reads and Cq values correlated modestly: -0.38, p = 0.01 for BE
and -0.32, p = 0.05 for GERD, relative quantification (fold changes) of miRNA expression between BE &GERD by NGS
correlated highly with qRT-PCR 0.86, p = 2.45E-11. Fold change correlations were unaffected when different thresholds of
NGS read counts were compared (>1000 vs. <1000, >500 vs. <500 and >100 vs. <100). The accuracy, precision and recall
of NGS to label a miRNA as differentially expressed were 0.71, 0.88 and 0.74 respectively.
Conclusion: Absolute NGS reads correlated modestly with qRT-PCR but fold changes correlated highly. NGS is robust at
relative but not absolute quantification of miRNA levels and accurate for high-throughput identification of differentially
expressed miRNA.
Keywords: Next generation sequencing, MicroRNA, qRT-PCR, Correlation, Barrett’s esophagusFindings
Next generation sequencing (NGS) is a significant advance-
ment over hybridization-based microarrays for microRNA
(miRNA) discovery. NGS can measure miRNA expression
across several orders of magnitude from 1 to 107. However,
the quantitative interpretation of the primary output of
NGS i.e. read counts for a miRNA sequence remains
unclear. The current practice is to validate NGS findings
by qRT-PCR [1-4]. However, the published studies have* Correspondence: abansal@kumc.edu
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unless otherwise stated.several limitations—a small number of biological sam-
ples [1,2], primarily qualitative analysis [3], introduction
of bias by selection for validation of only differentially
expressed miRNA by NGS [3] and lack of guidance on
low-versus high-abundance transcripts [1-4]. Specifically,
several unanswered questions remain. How do NGS read
counts correlate with Cq values on quantitative real-time
polymerase chain reaction (qRT-PCR)? Is there a thresh-
old copy number below which miRNA detection becomes
unreliable? What is the overall sensitivity and specificity of
NGS for identifying the miRNA of interest? How does
NGS perform at absolute quantification of a transcript
expression versus relative quantification between ex-
perimental and control groups? Does detection of differ-
ential expression of miRNA in a disease state depend on. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 List of miRNA analyzed with their expression
values by NGS
miRNA Average NGS read counts
GERD BE
hsa-mir-944 28.9 0.1
hsa-mir-466 20.1 4.3
hsa-mir-365a-5p 23.2 4.5
hsa-mir-3065-5p 36.3 8.3
hsa-mir-133a 1.9 14.4
hsa-mir-376a-3p 18.2 22.3
hsa-mir-296-5p 99.7 19.6
hsa-mir-299-5p 10.2 36.5
hsa-mir-1260b 448.5 43.4
hsa-mir-337-5p 7.7 71.5
hsa-mir-542-5p 10.7 77.6
hsa-mir-708-5p 967.7 78.8
hsa-mir-196b-5p 8.4 98.2
hsa-mir-487b 36.6 106.2
hsa-mir-486-5p 110.1 140.7
hsa-mir-224-5p 2052.5 210
hsa-mir-188-5p 210.8 288.3
hsa-mir-338-5p 31.4 489.5
hsa-mir-149-5p 3860.1 558
hsa-mir-196a-5p 37.7 586.6
hsa-mir-182-5p 1149.3 1238
hsa-mir-378c 1040.2 1723.2
hsa-mir-424-5p 491.7 1807.4
hsa-mir-339-5p 1430.4 2030.9
hsa-mir-203 90723.5 3569.2
hsa-let-7d-5p 3153.1 3594.9
hsa-mir-199b-5p 810.7 3880.1
hsa-mir-195-5p 1342.0 4248.0
hsa-mir-15b-5p 10763.4 5651.0
hsa-mir-194-5p 72.4 8209.3
hsa-mir-205-5p 291365 11835
hsa-mir-215 1152.4 69250
hsa-mir-145-5p 16925.6 1.0681e + 05
hsa-let-7a-5p 27926.4 20798
hsa-mir-192-5p 4710.6 2.4061e + 05
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malignant condition for rapidly increasing esophageal
adenocarcinoma and is a complication of Gastroesophageal
Reflux Disease (GERD) [5]. Here we present the systematic
comparison of miRNA expression by NGS and qRT-PCR
in well-characterized patients with BE and GERD.
Methods
Study design and patient selection
We previously sequenced the miRNA transcriptome in
GERD and BE [6] and evaluated 14 differentially expressed
miRNAs by qRT-PCR. For the current analysis, we ana-
lyzed an additional 22 miRNAs that were not differentially
expressed by NGS. These additional miRNAs were ran-
domly selected to represent the varying level of expression
by NGS in GERD and BE tissues and to allow us to calcu-
late NGS performance in an unbiased manner. Thus, we
evaluated a total of 36 miRNA by qRT-PCR (Table 1).
Patients with GERD and BE were selected from a pro-
spective tissue and serum repository (Clinical Trials.gov #
NCT00574327). The details of the repository, defini-
tions and inclusion and exclusion criteria have been de-
scribed previously [6]. The repository was created with
approval by the Human Subjects Committee and the Re-
search and Development Committee of the Institutional
Review Board, Veterans Affairs Medical Center, Kansas
City, Missouri. The repository has been annually approved
since 2005. All patients sign an IRB approved informed
consent prior to inclusion in the registry that allows us to
store samples for future research related to GERD and BE.
The approval number for the patient registry is ePRO-
MISE PS0035 as determined under the institutional regu-
lations. Briefly, BE is defined as presence of columnar
lined esophagus on endoscopy with demonstration of
intestinal metaplasia in biopsies. GERD is defined on
the basis of presence of heartburn and/or regurgitation
on a standardized and validated questionnaire. GERD
patients are further sub-classified into those with ero-
sive esophagitis (EE) and those without (Non-erosive re-
flux disease, NERD) based on the findings of esophagitis
(or lack thereof) on endoscopy. To study a homogeneous
population, for this study we included only those GERD
patients who had EE. The initial NGS cohort was com-
prised of 11 patients, five with GERD and six with BE, all
patients also underwent qRT-pCR. We also tested all of
the 36 miRNAs in an independent cohort of 20 GERD
and 27 BE patients by qRT-PCR.
Next generation sequencing
RNA (<70 nucleotides) was subjected to NGS as previously
described [6] and read sequences were aligned onto version
(v18) of miRBase, a repository of up-to-date miRNA infor-
mation of many species including human. Alignment was
performed using the bowtie short-read aligner software(version 0.12.7). NGS read counts for a specific miRNA
were expressed as number of counts for that miRNA/
million miRNA reads. After normalized read counts were
obtained, a state of the art statistical model for NGS differ-
ential expression analysis “R” package called DESeq [7]
was used. MicroRNA with p-values <0.05 (adjusted for
false discovery rate of 5%) were considered differentially
expressed.
Table 2 NGS read counts and distribution of Cq values
NGS reads Average Cq values Average delta Cq values
0-10 29.7 8.6
11-100 28.5 9.1
101-1000 29.1 7.7
1001-10000 27.2 6.6
10001-100000 25.3 3.2
>100000 21.1 1.4
NGS, next generation sequencing, NGS reads for a specific miRNA refers to the
counts/million miRNA reads.
Cq, threshold value on qRT-PCR.
deltaCq, Cq(miRNA)-Cq(RNU6B).
Table 3 Distribution of NGS reads based on Cq and delta
Cq values
Table 3a Table 3b
Cq values Average NGS reads delta Cq values Average NGS reads
<20 54996 <0 50428
20-24 75764 0-4 30414
25-29 2621 5-9 1485
30-34 2466 10-14 955
35-39 383 15-19 435
NGS, next generation sequencing.
Cq, threshold value on qRT-PCR.
delta Cq, Cq(miRNA)-Cq(RNU6B).
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Quantitative real-time polymerase chain reaction (qRT-
PCR) was performed as described previously [6] using
50 ηg RNA in custom designed low density array plates
from Applied Biosystems. Each sample was run in tripli-
cate and the mean of this technical replicate was used in
subsequent calculations. The threshold cycles (Cq) were
set to be in the doubling phase of the PCR amplification
runs. The Cq values for the target amplicon were nor-
malized by subtracting the Cq value of RNU6B to create
a delta Cq. This delta Cq was used to determine the
relative fold differences using the delta-delta Cq method.
Statistical analysis
Pearson’s correlation coefficients were calculated for the
log2 transformed, normalized copy numbers by NGS and
Cq and delta Cq values by qRT-PCR. Fold changes on
NGS and qRT-PCR were compared. We also calculated
the accuracy, precision and recall of NGS for the differen-
tially expressed miRNA considering qRT-PCR as the gold
standard. A miRNA was labeled as differentially expressed
by qRT-PCR in two different ways for purpose of the ana-
lysis—either log2 fold change > 2 or a p-value <0.05. True
positives were defined as differentially expressed miRNA
on NGS as well as qRT-PCR with the same direction of
fold change. False positives were defined as differentially
expressed miRNA on NGS but not by qRT-PCR or if the
direction of fold change was opposite between NGS and
qRT-PCR. Descriptive statistics were employed to evaluate
the NGS dataset for a threshold copy number for reliable
qRT-PCR detection. A p value of <0.05 was considered
significant.
Results
The average NGS read counts (reads per million) for all
miRNA in BE samples were 1060 per sample, median
3.3, 25th-75th percentile 0.74-26.8 (range 0.59-298,713.3).
The average NGS read counts for all miRNA in GERD
samples were 1415 per sample, median 3.5, 25th-75th
percentile 0.87-27.5 (range 0.63-614,409.9). The normal-
ized data were previously deposited at NCBI bioproject
repository (accession# PRJNA178304) (http://www.ncbi.
nlm.nih.gov/bioproject) [6]. We found that the overall
correlation coefficients between NGS reads and Cq cycles
for BE and GERD patients in the initial cohort of 11 pa-
tients were -0.37 (-0.33 to -0.52) and -0.33 (-0.31 to -0.47)
respectively, both p < 0.05. We subcategorized miRNA ex-
pression based on NGS read counts and compared PCR
results across these categories (Table 2). The Cq values
were inversely proportional to the NGS read count. For
reads > 1000, Cq values increased by ~ two cycles for every
10-fold increase in NGS reads. Since Cq cycles are loga-
rithmic, a change of two cycles indicates a fourfold change
in abundance of the particular miRNA (Table 2). We alsocategorized miRNAs based on their Cq values and found
that the NGS read counts progressively decreased with in-
creasing Cq values (Table 3a). Of note, if the Cq values
were higher than 35, the average NGS reads were much
lower (Table 3b). Thus, a low-abundance transcript on
PCR is likely to have low abundance by NGS. However,
vice versa is not true. Cq cycles were still in the range of
28-29 for low NGS reads of 1-100 (Table 2). Whether
these miRNA of low abundance by NGS are of biological
significance needs to be examined.
The primary purpose of a high-throughput technology is
to detect molecular changes across groups. Presumably the
differentially expressed molecular factors are the ones likely
to be associated with the observed phenotype. We vali-
dated the initial NGS results in an independent validation
cohort of 47 patients. Overall, the validation rate by qRT-
PCR of differentially expressed miRNA by NGS was 73%.
We compared fold changes between BE/GERD by NGS to
the fold changes predicted by qRT-PCR and found the cor-
relation to be high, 0.86 (0.68-0.9, p = 2.45E-11) (Figure 1).
We did not find any difference in the correlation of fold
changes when different thresholds of miRNA expression
by NGS were compared. Correlation coefficients were
0.84 (0.57-0.94) vs. 0.80 (0.56-0.91) for miRNA with NGS
reads ≥ 1000 versus <1000, 0.82 (0.58-0.93) vs. 0.81 (0.58-
0.92) for reads ≥ 500 versus <500 and 0.80 (0.57-0.91)
versus 0.89 (0.76-0.98) for reads ≥100 versus <100.
Figure 1 Graph depicts the correlation between fold changes
for the individual miRNA expression values by next generation
sequencing (NGS) and qRT-PCR. The fold changes by NGS were
log2 transformed. The line highlights the degree of fit indicating a
high correlation.
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NGS compared to qRT-PCR. We used two different cri-
teria, first, we used a p value of <0.05 on PCR to define
differential expression. Based on the p-value criteria, NGS
had an accuracy of 0.71, precision of 0.87 and recall of
0.74 with an f-measure of 0.80. Second, we used a com-
monly applied criterion of 2-fold change to define differ-
ential expression. Based on the fold change criteria, NGS
had an accuracy of 0.75, precision of 0.88 and recall of
0.79 with an f-measure of 0.83.
Discussion
To summarize, we made two main observations—first,
although there is a significant correlation between the
NGS read counts and PCR Cq values, NGS is only mod-
estly accurate at absolute quantification and second, there
was a high degree of correlation between NGS and PCR
in fold changes for differentially expressed miRNAs across
the GERD and BE groups. This correlation was similar for
low-abundance versus high-abundance transcripts by NGS.
These findings are significant for investigators focused on
making miRNA discoveries driving a disease state as NGS
datasets are generally limited because of cost restraints.
The differences in accuracy for absolute versus relative
quantification can be explained on the basis of bias intro-
duced by the library preparation method [8]. The library
preparation method may preferentially amplify some miR-
NAs but this bias is miRNA-specific and systematic acrossbiologic states thus allowing for differential expression to
be robust. Arguably, the differential expression metric is
the most biologically relevant.
qRT-PCR and hybridization-based arrays are other
methods for high-throughput miRNA detection. Several
studies have compared NGS and qRT-PCR for miRNA
expression [1-4]. However, the published studies do not
provide enough quantitative details with regards to per-
formance of low- versus high-abundance transcripts by
NGS. Others are limited by semi-quantitative analysis and
validation biased towards miRNA transcripts found to be
differentially expressed by NGS [3]. Validation of only
those miRNAs differentially expressed by NGS may over-
estimate its performance. Considering hybridization-based
microarrays, studies suggest platform dependent perform-
ance for microarrays [1,9].
An important parameter for a high-throughput method
is its validation rate. Our overall validation rate for NGS
was 73%, significantly higher than the validation rates of
30-40% reported for microarray based methods [10,11]. A
potential microarray limitation is its reduced ability to de-
tect differential expression at low expression levels of the
miRNA [9]. NGS fold changes did not depend on the ex-
pression level in the current dataset. Thus, NGS may have
an advantage over microarray for evaluation of low abun-
dance transcripts. With decreasing costs, potential for iden-
tification of novel transcripts and further standardization of
NGS methods, NGS is likely to replace miRNA microarrays
as the technique of choice for high-throughput analysis of
miRNA expression.
Our study has some limitations. We studied SOLiD but
not the more prevalent Illumina sequencing platform.
NGS technology is costly. Also, NGS requires considerable
RNA input that makes it difficult to test multiple platforms
simultaneously. qRT-PCR may not be the perfect gold
standard compared to techniques such as northern blotting
and cloning but it is commonly used to validate NGS re-
sults prior to embarking on the functional studies. Our
study argues that the step of PCR validation may not be
necessary if the primary goal is to identify miRNAs that
change between control and disease states. A “spike-in”
test using synthetic miRNAs could have been useful but
would have controlled for technical but not biological vari-
ance. As discussed earlier, the library preparation during
NGS may be biased towards specific miRNAs but this
bias affects specific miRNAs and not specific samples.
Inclusion of a few artificial spike-in tests would have not
controlled for the miRNA specific effect of the library
preparation method and would not have changed the
overall conclusions.
Conclusions
NGS has modest correlation with quantitative PCR for ab-
solute quantification but high correlation for differential
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validation rate for the differentially expressed miRNAs.
Thus, NGS is ideally suited for biologic studies to further
understand the role of miRNA in premalignant gastro-
intestinal neoplasia.
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